ARS Pharmaceuticals, Inc. (SPRY)

In February 2026, shares closed down due to investor caution amid high short interest, but analysts maintained a 'Moderate Buy' rating. In early February 2026, shares were unchanged but gained in after-hours trading after a William Blair analyst reaffirmed a 'Buy' rating. In late January/early February 2026, the stock declined despite positive regulatory news from Europe. In January 2026, the stock increased following neffy's approval in China. In November 2025, the company reported a net loss but had significant cash reserves to fund neffy's commercial growth. In August 2025, ARS Pharma reported a significant increase in neffy two-pack unit weekly volumes and HCPs prescribing neffy. In July 2025, Raymond James reiterated a 'Strong Buy' rating and increased neffy net sales estimates. In September 2023, the company received a Complete Response Letter from the FDA, causing shares to plummet.

There is an expectation of a summer peak season for epinephrine product sales, suggesting a seasonal increase in demand for products like neffy during the warmer months.

ARS Pharmaceuticals, Inc. (SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. Its primary product is neffy (epinephrine nasal spray), the first FDA-approved needle-free epinephrine product for Type I allergic reactions, including anaphylaxis. The company aims to provide patient-friendly treatments that address issues related to needle-related risks, device portability, and ease of use.

ARS Pharmaceuticals, Inc. is headquartered in San Diego, California, United States. Neffy has gained regulatory approval in Europe and China. The European Medicines Agency's CHMP issued a positive opinion recommending expanded marketing authorization for EURneffy to include a 1 mg nasal adrenaline spray for pediatric patients. Neffy has also been approved in China as the first and only community-use epinephrine product for allergic reactions.

ARS Pharmaceuticals has actively worked to build neffy's brand reputation through a direct-to-consumer (DTC) marketing campaign, which significantly increased consumer awareness. Positive analyst sentiment reflects a favorable view of the company's commercialization efforts. FDA approval of neffy for adults and pediatric patients, along with the European Medicines Agency's positive opinion and approval in China, further bolster its global standing.

ARS Pharmaceuticals, Inc. has a significant institutional ownership base, with 334 institutional owners and shareholders holding 68.16% of shares outstanding. Major institutional owners include RA Capital Management, L.P., Orbimed Advisors LLC, and BlackRock, Inc. Individual insiders own 8.72% of the company, including Richard Lowenthal and Sarina Tanimoto.